Granocyte 13 is a brand name for a medication that contains the active ingredient lenograstim, which is a type of granulocyte colony-stimulating factor (G-CSF). It is a recombinant form of human G-CSF and is produced using biotechnology. Granocyte 13 is primarily used to stimulate the production of white blood cells (granulocytes) in patients who have undergone chemotherapy, bone marrow transplantation, or are suffering from severe chronic neutropenia. The increase in white blood cells helps to reduce the risk of infection in these patients. It is administered via injection and is known for its role in enhancing the immune system's ability to fight infections. Granocyte 13 is a critical medication in the management of neutropenia and is used under the guidance of healthcare professionals in a clinical setting.